Compare Neurocrine Biosciences Inc (NBIX) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Tilray Brands Inc — how do they compare? Neurocrine Biosciences Inc trades at $151.61 (market cap $16.46B), while Tilray Brands Inc trades at $4.78 (market cap $649.42M). The key difference: Neurocrine Biosciences Inc is far larger — about 25.3× Tilray Brands Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | TLRY | |
|---|---|---|
Market Cap | $16.46B | $649.42M |
Sector | Health | Health |
52-Week High | $185.50 | $21.00 |
52-Week Low | $123.10 | $3.88 |
Enterprise Value | $16.48B | $816.55M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
